Chronic Obstructive Pulmonary Disease: A Concise Review

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      PDF Download and 24 Hours Online Access
      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Medical Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Miniño A.M.
        • Xu J.
        • Kochanck K.D.
        Preliminary data for 2008.
        Natl Vital Stat Rep. 2010; 59
        • National Heart Lung and Blood Institute
        Morbidity and mortality: 2009 chart book on cardiovascular, lung, and blood diseases.
        National Heart, Lung, and Blood Institute, Bethesda (MD)2009
        • Gross N.J.
        What is this thing called love?—or, defining asthma.
        Am Rev Respir Dis. 1980; 121: 203-204
      1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for Diagnosis, Management and Prevention of COPD. GOLD; 2010. Available at: http://www.goldcopd.org/. Accessed August 27, 2011.

        • Wright D.T.
        • Cohn L.A.
        • Li H.
        • et al.
        Interactions of oxygen radicals with airway epithelium.
        Environ Health Perspect. 1994; 102: 85-90
        • Blanc P.D.
        • Iribarren C.
        • Trupin L.
        • et al.
        Occupational exposures and the risk of COPD: dusty trades revisited.
        Thorax. 2009; 64: 6-12
        • Po J.Y.
        • FitzGerald J.M.
        • Carlsten C.
        Respiratory disease associated with solid biomass fuel exposure in rural women and children: systematic review and meta-analysis.
        Thorax. 2011; 66: 232-239
        • Lee M.H.
        • Hancox R.J.
        Effects of smoking cannabis on lung function.
        Expert Rev Respir Med. 2011; 5: 537-547
        • Ko F.W.
        • Hui D.S.
        Outdoor air pollution: impact on chronic obstructive pulmonary disease patients.
        Curr Opin Pulm Med. 2009; 15: 150-157
        • Nakamura H.
        Genetics of COPD.
        Allergol Int. 2011; 60: 253-258
        • Pillai D.R.
        • Shahinas D.
        • Buzina A.
        • et al.
        Genome-wide dissection of globally emergent multi-drug resistant serotype 19A Streptococcus pneumoniae.
        BMC Genomics. 2009; 10: 642
        • Han M.K.
        Update in chronic obstructive pulmonary disease in 2010.
        Am J Respir Crit Care Med. 2011; 183: 1311-1315
        • Pillai S.G.
        • Ge D.
        • Zhu G.
        • et al.
        A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci.
        PLoS Genet. 2009; 5: e1000421
        • Sinderby C.
        • Spahija J.
        • Beck J.
        Changes in respiratory effort sensation over time are linked to the frequency content of diaphragm electrical activity.
        Am J Respir Crit Care Med. 2001; 163: 905-910
        • Seibold M.A.
        • Schwartz D.A.
        The lung: the natural boundary between nature and nurture.
        Annu Rev Physiol. 2011; 73: 457-478
        • Regan E.A.
        • Hokanson J.E.
        • Murphy J.R.
        • et al.
        Genetic epidemiology of COPD (COPDGene) study design.
        COPD. 2010; 7: 32-43
        • Guerra S.
        Overlap of asthma and chronic obstructive pulmonary disease.
        Curr Opin Pulm Med. 2005; 11: 7-13
        • Camp P.G.
        • O’Donnell D.E.
        • Postma D.S.
        Chronic obstructive pulmonary disease in men and women: myths and reality.
        Proc Am Thorac Soc. 2009; 6: 535-538
        • Sin D.D.
        • Cohen S.B.
        • Day A.
        • et al.
        Understanding the biological differences in susceptibility to chronic obstructive pulmonary disease between men and women.
        Proc Am Thorac Soc. 2007; 4: 671-674
        • Tam A.
        • Morrish D.
        • Wadsworth S.
        • et al.
        The role of female hormones on lung function in chronic lung diseases.
        BMC Womens Health. 2011; 11: 24
        • Spurzem J.R.
        • Rennard S.I.
        Pathogenesis of COPD.
        Semin Respir Crit Care Med. 2005; 26: 142-153
        • Hogg J.C.
        • Chu F.
        • Utokaparch S.
        • et al.
        The nature of small-airway obstruction in chronic obstructive pulmonary disease.
        N Engl J Med. 2004; 350: 2645-2653
        • Kirkham P.
        • Rahman I.
        Oxidative stress in asthma and COPD: antioxidants as a therapeutic strategy.
        Pharmacol Ther. 2006; 111: 476-494
        • Gosselink J.V.
        • Hayashi S.
        • Elliott W.M.
        • et al.
        Differential expression of tissue repair genes in the pathogenesis of chronic obstructive pulmonary disease.
        Am J Respir Crit Care Med. 2010; 181: 1329-1335
        • Vogelmeier C.F.
        • Wouters E.F.
        Treating the systemic effects of chronic obstructive pulmonary disease.
        Proc Am Thorac Soc. 2011; 8: 376-379
        • Lee S.D.
        • Ju G.
        • Choi J.A.
        • et al.
        The association of oxidative stress with central obesity in obstructive sleep apnea.
        Sleep Breath. 2011; ([Epub ahead of print])
        • Buist A.S.
        • Nagy J.M.
        Relationship between smoking and the single breath nitrogen washout.
        Scand J Respir Dis Suppl. 1976; 95: 108-116
        • Lee R.
        • McNicholas W.T.
        Obstructive sleep apnea in chronic obstructive pulmonary disease patients.
        Curr Opin Pulm Med. 2011; 17: 79-83
        • Seemungal T.A.
        • Donaldson G.C.
        • Paul E.A.
        • et al.
        Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease.
        Am J Respir Crit Care Med. 1998; 157: 1418-1422
        • Buist A.S.
        • Sexton G.J.
        • Nagy J.M.
        • et al.
        The effect of smoking cessation and modification on lung function.
        Am Rev Respir Dis. 1976; 114: 115-122
        • Mohamed Hoesein F.A.
        • Zanen P.
        • Lammers J.W.
        Lower limit of normal or FEV1/FVC < 0.70 in diagnosing COPD: an evidence-based review.
        Respir Med. 2011; 105: 907-915
        • Glaab T.
        • Vogelmeier C.
        • Buhl R.
        Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitations.
        Respir Res. 2010; 11: 79
        • Sethi S.
        • Evans N.
        • Grant B.J.
        • et al.
        New strains of bacteria and exacerbations of chronic obstructive pulmonary disease.
        N Engl J Med. 2002; 347: 465-471
        • Wu J.
        • Sin D.D.
        Improved patient outcome with smoking cessation: when is it too late?.
        Int J Chron Obstruct Pulmon Dis. 2011; 6: 259-267
        • Cahill K.
        • Stead L.F.
        • Lancaster T.
        Nicotine receptor partial agonists for smoking cessation.
        Cochrane Database Syst Rev. 2011; 2 (CD006103)
        • Ries A.L.
        • Bauldoff G.S.
        • Carlin B.W.
        • et al.
        Pulmonary rehabilitation: joint ACCP/AACVPR evidence-based clinical practice guidelines.
        Chest. 2007; 131: 4S-42S
        • Rice K.L.
        • Dewan N.
        • Bloomfield H.E.
        • et al.
        Disease management program for chronic obstructive pulmonary disease: a randomized controlled trial.
        Am J Respir Crit Care Med. 2010; 182: 890-896
      2. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party.
        Lancet. 1981; 1: 681-686
        • Anthonisen N.R.
        Long-term oxygen therapy.
        Ann Intern Med. 1983; 99: 519-527
        • Qaseem A.
        • Wilt T.J.
        • Weinberger S.E.
        • et al.
        Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society.
        Ann Intern Med. 2011; 155: 179-191
        • Celli B.R.
        • MacNee W.
        Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper.
        Eur Respir J. 2004; 23: 932-946
        • Wise R.A.
        • Tashkin D.P.
        Optimizing treatment of chronic obstructive pulmonary disease: an assessment of current therapies.
        Am J Med. 2007; 120: S4-S13
        • Sin D.D.
        • McAlister F.A.
        • Man S.F.
        • et al.
        Contemporary management of chronic obstructive pulmonary disease: scientific review.
        JAMA. 2003; 290: 2301-2312
        • Nelson H.S.
        • Weiss S.T.
        • Bleecker E.R.
        • et al.
        The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol.
        Chest. 2006; 129: 15-26
        • Salpeter S.R.
        • Ormiston T.M.
        • Salpeter E.E.
        Meta-analysis: respiratory tolerance to regular beta2-agonist use in patients with asthma.
        Ann Intern Med. 2004; 140: 802-813
        • Tashkin D.P.
        • Celli B.
        • Senn S.
        • et al.
        A 4-year trial of tiotropium in chronic obstructive pulmonary disease.
        N Engl J Med. 2008; 359: 1543-1554
        • Singh S.
        • Loke Y.K.
        • Furberg C.D.
        Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.
        JAMA. 2008; 300: 1439-1450
        • Dorinsky P.M.
        • Reisner C.
        • Ferguson G.T.
        • et al.
        The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD.
        Chest. 1999; 115: 966-971
        • van Noord J.A.
        • Aumann J.L.
        • Janssens E.
        • et al.
        Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD.
        Eur Respir J. 2005; 26: 214-222
        • Alsaeedi A.
        • Sin D.D.
        • McAlister F.A.
        The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials.
        Am J Med. 2002; 113: 59-65
        • Hanania N.A.
        • Darken P.
        • Horstman D.
        • et al.
        The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD.
        Chest. 2003; 124: 834-843
        • Tashkin D.P.
        Budesonide and formoterol in a single pressurized metered-dose inhaler for treatment of COPD.
        Expert Rev Respir Med. 2010; 4: 703-714
        • Rennard S.I.
        • Tashkin D.P.
        • McElhattan J.
        • et al.
        Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial.
        Drugs. 2009; 69: 549-565
        • Tashkin D.P.
        • Rennard S.I.
        • Martin P.
        • et al.
        Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial.
        Drugs. 2008; 68: 1975-2000
        • Ferguson G.T.
        • Anzueto A.
        • Fei R.
        • et al.
        Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.
        Respir Med. 2008; 102: 1099-1108
        • Calverley P.M.
        • Anderson J.A.
        • Celli B.
        • et al.
        Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
        N Engl J Med. 2007; 356: 775-789
        • Wedzicha J.A.
        • Calverley P.M.
        • Seemungal T.A.
        • et al.
        The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide.
        Am J Respir Crit Care Med. 2008; 177: 19-26
        • Ernst P.
        • Gonzalez A.V.
        • Brassard P.
        • et al.
        Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia.
        Am J Respir Crit Care Med. 2007; 176: 162-166
        • Calverley P.M.
        • Stockley R.A.
        • Seemungal T.A.
        • et al.
        Reported pneumonia in patients with COPD: findings from the INSPIRE study.
        Chest. 2011; 139: 505-512
        • Sin D.D.
        • Tashkin D.
        • Zhang X.
        • et al.
        Budesonide and the risk of pneumonia: a meta-analysis of individual patient data.
        Lancet. 2009; 374: 712-719
        • Aaron S.D.
        • Vandemheen K.L.
        • Fergusson D.
        • et al.
        Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial.
        Ann Intern Med. 2007; 146: 545-555
        • Singh D.
        • Brooks J.
        • Hagan G.
        • et al.
        Superiority of “triple” therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD.
        Thorax. 2008; 63: 592-598
        • Gaebel K.
        • McIvor R.A.
        • Xie F.
        • et al.
        Triple therapy for the management of COPD: a review.
        COPD. 2011; 8: 206-243
        • Ford P.A.
        • Durham A.L.
        • Russell R.E.
        • et al.
        Treatment effects of low-dose theophylline combined with an inhaled corticosteroid in COPD.
        Chest. 2010; 137: 1338-1344
        • To Y.
        • Ito K.
        • Kizawa Y.
        • et al.
        Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease.
        Am J Respir Crit Care Med. 2010; 182: 897-904
        • Rabe K.F.
        • Hiemstra P.S.
        Theophylline for chronic obstructive pulmonary disease? Time to move on.
        Am J Respir Crit Care Med. 2010; 182: 868-869
        • Ram F.S.
        • Rodriguez-Roisin R.
        • Granados-Navarrete A.
        • et al.
        WITHDRAWN: Antibiotics for exacerbations of chronic obstructive pulmonary disease.
        Cochrane Database Syst Rev. 2011; 1 (CD004403)
        • Lipworth B.J.
        Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease.
        Lancet. 2005; 365: 167-175
        • Puhan M.
        Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
        Cochrane Database Syst Rev. 2011; 8 (ED000028)
        • O’Byrne P.M.
        • Gauvreau G.
        Phosphodiesterase-4 inhibition in COPD.
        Lancet. 2009; 374: 665-667
        • Altenburg J.
        • de Graaff C.S.
        • van der Werf T.S.
        • et al.
        Immunomodulatory effects of macrolide antibiotics—part 2: advantages and disadvantages of long-term, low-dose macrolide therapy.
        Respiration. 2011; 81: 75-87
        • Altenburg J.
        • de Graaff C.S.
        • van der Werf T.S.
        • et al.
        Immunomodulatory effects of macrolide antibiotics—part 1: biological mechanisms.
        Respiration. 2011; 81: 67-74
        • Tamaoki J.
        The effects of macrolides on inflammatory cells.
        Chest. 2004; 125 ([quiz: 51S]): 41S-50S
        • Albert R.
        Chronic azithromycin decreases the frequency of chronic obstructive pulmonary disease exacerbations.
        Am J Respir Crit Care Med. 2011; 183: A6416
        • Young R.P.
        • Hopkins R.
        • Eaton T.E.
        Pharmacological actions of statins: potential utility in COPD.
        Eur Respir Rev. 2009; 18: 222-232
        • Dobler C.C.
        • Wong K.K.
        • Marks G.B.
        Associations between statins and COPD: a systematic review.
        BMC Pulm Med. 2009; 9: 32
        • Mancini G.B.
        • Etminan M.
        • Zhang B.
        • et al.
        Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease.
        J Am Coll Cardiol. 2006; 47: 2554-2560
        • Vestbo J.
        • Tan L.
        • Atkinson G.
        • et al.
        A controlled trial of 6-weeks’ treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD.
        Eur Respir J. 2009; 33: 1039-1044
        • Holverda S.
        • Rietema H.
        • Bogaard H.J.
        • et al.
        Acute effects of sildenafil on exercise pulmonary hemodynamics and capacity in patients with COPD.
        Pulm Pharmacol Ther. 2008; 21: 558-564
        • Janssens W.
        • Bouillon R.
        • Claes B.
        • et al.
        Vitamin D deficiency is highly prevalent in COPD and correlates with variants in the vitamin D-binding gene.
        Thorax. 2010; 65: 215-220
        • Janssens W.
        • Lehouck A.
        • Carremans C.
        • et al.
        Vitamin D beyond bones in chronic obstructive pulmonary disease: time to act.
        Am J Respir Crit Care Med. 2009; 179: 630-636
        • Janssens W.
        • Mathieu C.
        • Boonen S.
        • et al.
        Vitamin D deficiency and chronic obstructive pulmonary disease: a vicious circle.
        Vitam Horm. 2011; 86: 379-399
        • Black P.N.
        • Scragg R.
        Relationship between serum 25-hydroxyvitamin d and pulmonary function in the third national health and nutrition examination survey.
        Chest. 2005; 128: 3792-3798
        • Connors Jr., A.F.
        • Dawson N.V.
        • Thomas C.
        • et al.
        Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments).
        Am J Respir Crit Care Med. 1996; 154: 959-967
        • Sin D.D.
        • Tu J.V.
        Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease.
        Am J Respir Crit Care Med. 2001; 164: 580-584
        • Sethi S.
        Infectious etiology of acute exacerbations of chronic bronchitis.
        Chest. 2000; 117: 380S-385S
        • Bakri F.
        • Brauer A.L.
        • Sethi S.
        • et al.
        Systemic and mucosal antibody response to Moraxella catarrhalis after exacerbations of chronic obstructive pulmonary disease.
        J Infect Dis. 2002; 185: 632-640
        • Abe Y.
        • Murphy T.F.
        • Sethi S.
        • et al.
        Lymphocyte proliferative response to P6 of Haemophilus influenzae is associated with relative protection from exacerbations of chronic obstructive pulmonary disease.
        Am J Respir Crit Care Med. 2002; 165: 967-971
        • Murphy T.F.
        • Sethi S.
        • Hill S.L.
        • et al.
        Inflammatory markers in bacterial exacerbations of COPD.
        Am J Respir Crit Care Med. 2002; 165: 132
        • Fishman A.
        • Martinez F.
        • Naunheim K.
        • et al.
        A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema.
        N Engl J Med. 2003; 348: 2059-2073
      3. Patients at high risk of death after lung-volume-reduction surgery.
        N Engl J Med. 2001; 345: 1075-1083
        • Patel N.
        • DeCamp M.
        • Criner G.J.
        Lung transplantation and lung volume reduction surgery versus transplantation in chronic obstructive pulmonary disease.
        Proc Am Thorac Soc. 2008; 5: 447-453
        • Sethi S.
        The role of antibiotics in acute exacerbations of chronic obstructive pulmonary disease.
        Curr Infect Dis Rep. 2003; 5: 9-15
        • Ernst A.
        • Anantham D.
        Bronchoscopic lung volume reduction.
        Pulm Med. 2011; 2011: 610802